5YI Stock Overview
Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Nyxoah S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €7.70 |
| 52 Week High | €17.70 |
| 52 Week Low | €3.62 |
| Beta | 0.55 |
| 1 Month Change | -17.03% |
| 3 Month Change | n/a |
| 1 Year Change | 8.76% |
| 3 Year Change | -57.55% |
| 5 Year Change | n/a |
| Change since IPO | -45.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| 5YI | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | -13.7% | 0.7% | 2.5% |
| 1Y | 8.8% | -4.6% | 6.0% |
Return vs Industry: 5YI exceeded the German Medical Equipment industry which returned -4.9% over the past year.
Return vs Market: 5YI exceeded the German Market which returned 5.4% over the past year.
Price Volatility
| 5YI volatility | |
|---|---|
| 5YI Average Weekly Movement | 99.1% |
| Medical Equipment Industry Average Movement | 4.5% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.4% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 5YI's share price has been volatile over the past 3 months.
Volatility Over Time: 5YI's weekly volatility has increased from 42% to 99% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 147 | Olivier Taelman | www.nyxoah.com |
Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
Nyxoah S.A. Fundamentals Summary
| 5YI fundamental statistics | |
|---|---|
| Market cap | €233.48m |
| Earnings (TTM) | -€43.21m |
| Revenue (TTM) | €4.35m |
53.7x
P/S Ratio-5.4x
P/E RatioIs 5YI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 5YI income statement (TTM) | |
|---|---|
| Revenue | €4.35m |
| Cost of Revenue | €1.66m |
| Gross Profit | €2.69m |
| Other Expenses | €45.90m |
| Earnings | -€43.21m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 14, 2024
| Earnings per share (EPS) | -1.51 |
| Gross Margin | 61.91% |
| Net Profit Margin | -993.84% |
| Debt/Equity Ratio | 8.9% |
How did 5YI perform over the long term?
See historical performance and comparison